vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
Key Highlights
- ➤54% of adults using AID systems experienced at least one hypoglycemia-related burden
- ➤24% of AID users reported frequent Level 2 hypoglycemia
- ➤Cadisegliatin is being evaluated in a U.S. Phase 3 T1D study
- ➤Cadisegliatin received FDA Breakthrough Therapy designation
- ➤vTv presented research at Breakthrough T1D Clinical & Research Congress 2026
Expert Statements
Paul Sekhri, Chairman, President, and Chief Executive Officer of vTv Therapeutics
“These findings reinforce that, despite meaningful advances in insulin delivery technology, insulin has its limitations and hypoglycemia continues to shape daily glucose management for many people with type 1 diabetes”
Paul Sekhri, Chairman, President, and Chief Executive Officer of vTv Therapeutics
“The fact that more than half of adults using AID systems still experience clinically meaningful hypoglycemia-related burdens underscores the need for additional treatment options that can work alongside insulin and existing technologies to help address this burden.”
Richard Wood, Chief Executive Officer of dQ&A Market Research, Inc.
“Our mission at dQ&A is to serve as the voice of people living with diabetes. These findings highlight the challenges that many people with T1D continue to experience with hypoglycemia, including those using technologies such as AID,”
Richard Wood, Chief Executive Officer of dQ&A Market Research, Inc.
“We are excited by the prospect of new therapies that could complement existing technologies and further alleviate this burden to give people greater confidence and freedom in their everyday lives.”
HIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (link)(Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that Chief Medical Officer Thomas Strack, M.D., Ph.D., presented research spotlighting hypoglycemia-related burdens among adults with T1D using automated insulin delivery (AID) systems at the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) in Philadelphia, PA. Cadisegliatin is a potential first-in-class, liver-selective glucokinase activator (GKA) being evaluated as an oral adjunctive therapy to insulin for the treatment of T1D. “A Cumulative Population View of Hypoglycemia-Related Burdens in T1D Adults Using AID Systems," a quantitative online research initiative commissioned by vTv Therapeutics and conducted by dQ&A Market Research, Inc., examined the prevalence of clinically meaningful hypoglycemia-related burdens among 674 adults with T1D of whom 429 were using AID systems. Among adult AID system users, 24% reported experiencing frequent Level 2 hypoglycemia, defined as daily, almost daily, or a few moderate hypoglycemic events (<54 mg/dL) in a typical week. 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness of hypoglycemia, defined as never or rarely noticing or feeling the symptoms of hypoglycemia. Among those with A1C >7%, 49% strongly agreed that they often keep their blood glucose higher to avoid hypoglycemia or that they would target lower glucose levels if not for the risk of hypoglycemia.
Get started
Create a free account to read the full story.